The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...

More information: Robert Wood et al, Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi ...

Thirty-six percent of patients treated with omalizumab were able to tolerate 2000mg of peanut protein and 2 other food allergens without experiencing an allergic reaction compared with 19% of OIT ...

Last year, the US Food and Drug Administration (FDA) approved omalizumab— an injectable medication already used for allergic asthma, chronic hives, and nasal polyps — for food allergies in ...

Director of the Eudowood Division of Allergy, Immunology and Rheumatology at Johns Hopkins Children’s Center, Robert Wood, MD led a clinical trial on omalizumab — an already FDA-approved drug ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respirator ...

Amneal is expanding its portfolio with omalizumab, a proposed biosimilar of Novartis AG’s Xolair. Omalizumab is a humanized monoclonal antibody that targets free immunoglobulin E. It is an ...

The approval was based on results from a phase III trial that confirmed the bioequivalence of the biosimilar, formerly known as CT-P39, to omalizumab in patients with chronic spontaneous urticaria.

Robert Wood, the director of the Eudowood Division of Allergy, Immunology, and Rheumatology at Johns Hopkins Children’s Center, led a clinical trial on omalizumab—an already FDA-approved drug ...